Morgan Stanley lifted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 285.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,412,653 shares of the biotechnology company’s stock after buying an additional 1,045,869 shares during the quarter. Morgan Stanley owned approximately 1.28% of BioCryst Pharmaceuticals worth $5,354,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of the stock. BlackRock Inc. boosted its position in BioCryst Pharmaceuticals by 2.6% during the second quarter. BlackRock Inc. now owns 8,925,891 shares of the biotechnology company’s stock valued at $33,831,000 after purchasing an additional 228,525 shares in the last quarter. Vanguard Group Inc. boosted its position in BioCryst Pharmaceuticals by 10.7% during the second quarter. Vanguard Group Inc. now owns 6,692,444 shares of the biotechnology company’s stock valued at $25,365,000 after purchasing an additional 648,937 shares in the last quarter. FMR LLC boosted its position in BioCryst Pharmaceuticals by 15.9% during the first quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after purchasing an additional 475,989 shares in the last quarter. Invesco Ltd. boosted its position in BioCryst Pharmaceuticals by 63.9% during the second quarter. Invesco Ltd. now owns 1,446,732 shares of the biotechnology company’s stock valued at $5,483,000 after purchasing an additional 563,822 shares in the last quarter. Finally, First Midwest Bank Trust Division bought a new stake in BioCryst Pharmaceuticals during the second quarter valued at about $1,791,000. 90.73% of the stock is currently owned by institutional investors.
Shares of NASDAQ BCRX opened at $2.38 on Wednesday. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.44 and a quick ratio of 1.43. The business has a 50-day simple moving average of $2.83 and a two-hundred day simple moving average of $4.25. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $9.95.
A number of equities research analysts recently weighed in on the company. ValuEngine raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. BidaskClub downgraded BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 4th. Finally, Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. BioCryst Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $9.08.
BioCryst Pharmaceuticals Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Recommended Story: How to calculate the intrinsic value of a stock
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.